ClinicalTrials.gg
CompletedNCT02165098Updated Mar 24, 2016

Cariprazine: Comparison of Slow- and Immediate-release Forms

A Phase 1 interventional study of Cariprazine prolonged release tablet A and Cariprazine prolonged release tablet B in Pharmacokinetic Profile, sponsored by Gedeon Richter Plc.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-24.

Sponsored by Gedeon Richter Plc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The investigators are doing this study to compare blood levels and side effects of cariprazine when it's taken as one of two 'slow release' tablets, or as an 'immediate release' capsule. The investigators will also find out if food affects the absorption of cariprazine into the bloodstream after a 'slow release' tablet.

Read the detailed description

Comparison of blood levels and side effects of cariprazine when it's taken as one of two 'slow release' tablets, or as an 'immediate release' capsule. We'll also find out if food affects the absorption of cariprazine into the bloodstream after a 'slow release' tablet.

02

Conditions studied

  • Pharmacokinetic Profile
03

In context

Lead sponsor

Gedeon Richter Plc. is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy Caucasian males aged 18-55 years with (BMI) ≥ 18 kg/m2 and ≤ 30 kg/m2
  • Have a semisupine pulse rate ≥ 40 bpm and ≤ 100 bpm during the vital sign assessment at screening and on admission (Day 1)
  • Agree to use an effective method of and not have their partners become pregnant throughout the study and for up to 4 months after the administration of the IMP, or have been sterilized for at least 1 year

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Cariprazine PR tablet B

    Cariprazine prolonged release tablet B - fed

    Drug: Cariprazine PR tablet B

  • Experimental
    Cariprazine PR tablet A

    Cariprazine prolonged release tablet A - fed

    Drug: Cariprazine PR tablet A

  • Experimental
    Cariprazine capsule

    Cariprazine capsule - fasted

    Drug: Cariprazine capsule

  • Experimental
    Cariprazine prolonged release tablet B

    Cariprazine prolonged release tablet B - fasted

    Drug: Cariprazine prolonged release tablet B

  • Experimental
    Cariprazine prolonged release tablet A

    Cariprazine prolonged release tablet A - fasted

    Drug: Cariprazine prolonged release tablet A

Interventions

  • DrugCariprazine prolonged release tablet A

    Cariprazine prolonged release tablet A - fasted

  • DrugCariprazine prolonged release tablet B

    Cariprazine prolonged release tablet B - fasted

  • Cariprazine capsule - fasted

  • DrugCariprazine PR tablet A

    Cariprazine Prolonged Release tablet A - fed

  • DrugCariprazine PR tablet B

    Cariprazine Prolonged Release tablet B - fed

06

What researchers measure

Primary outcomes

  1. C[max]

    Maximum Serum Concentration of the parent drug

    Time frame: 0-672 hours

  2. AUC

    Area Under the Serum Concentration-Time Curve of the parent drug

    Time frame: 0-672 hours

  3. T[max]

    Time to Reach the Maximum Serum Concentration of the parent drug

    Time frame: 0-672 hours

Secondary outcomes

  1. Other PK parameters of the parent drug

    Elimination half-life period (t1/2), Mean Residence Time (MRT), if applicable

    Time frame: 0-672 hours

  2. PK parameters of the metabolites, if applicable

    Maximum Serum Concentration (Cmax), Time to Reach the Maximum Serum Concentration (Tmax), (AUC0-t), Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC0-∞), Elimination half-life period (t1/2) and Mean Residence Time (MRT)

    Time frame: 0-672 hours

07

Study locations

1 site
  • Hammersmith Medicines Research
    London, NW10 7EW, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2014
First posted
Jun 17, 2014
Start
Jun 2014
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Last update
Mar 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02165098
Lead sponsor
Gedeon Richter Plc.
Responsible party
Sponsor
First posted
Jun 17, 2014
Start date
Jun 2014
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Mar 24, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion